Corporate Events

From April 1, 2025 to June 30, 2025, the company has repurchased 19,999,450 shares, representing 2.87% for $205.15 million. With this, the company has completed the repurchase of 148,631,236 shares, representing 19.59% for $1,500 million under the buyback announced on April 2, 2024.

The company closed its plan in June 2025.

Sumitomo Pharma Co., Ltd. provided consolidated earnings guidance for the half-year ending September 30, 2025. For the half year, the company expected revenue of JPY 207,000 million; Core operating profit of JPY 70,000 million; Operating profit of JPY 69,000 million; Net profit attributable to owners of parent of JPY 56,000 million; and Earnings per share of JPY 140.96.

Marubeni Global Pharma Co., Ltd. entered into Share Transfer Agreement to acquire 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) for ¥45.0 billion on April 1, 2025. A cash consideration of ¥45 billion will be paid by Marubeni Global Pharma Co., Ltd. The transaction is subject to subject to antitrust regulations. The expected completion of the transaction is from July 1, 2025 to September 30, 2025. Marubeni Global Pharma Co., Ltd. entered into Share Transfer Agreement to acquire 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on July 31, 2025.

Sumitomo Pharma Co., Ltd., Q1 2026 Earnings Call, Jul 31, 2025

Sawai Group Holdings Co., Ltd. (TSE:4887) agreed to acquire FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on March 28, 2025. The expected completion of the transaction is June 30, 2025. Sawai Group Holdings Co., Ltd. (TSE:4887) completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on June 30, 2025.

The board of directors of Sumitomo Pharma Co., Ltd. at its meeting held on May 13, 2025, approved retirement of Saeko Arai- Member, Board of Directors (Outside); Nobuhiro Endo- Member, Board of Directors (Outside); Takashi Kutsunai- Audit & Supervisory Board Member.

From January 1, 2025 to March 31, 2025, the company has repurchased 27,126,867 shares, representing 3.77% for $292.06 million. With this, the company has completed the repurchase of 128,631,786 shares, representing 16.72% for $1,294.85 million under the buyback announced on April 2, 2024.

Sumitomo Pharma Co., Ltd. announced that they will report Q1, 2026 results at 3:30 PM, Tokyo Standard Time on Jul 31, 2025

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 26, 2025, at 10:00 Tokyo Standard Time. Location: Hall on the 7th floor of the Company's Corporate Headquarters Building 6-8, Doshomachi 2-chome, Chuo-ku Osaka Japan Agenda: To consider business report, consolidated financial statements, and non-consolidated financial statements for the 205th fiscal year (from April 1, 2024 to March 31, 2025); to consider audit report of the accounting auditor and audit report of the audit & supervisory board on the consolidated financial statements; to consider partial amendments to the articles of incorporation; to consider election of six directors (excluding directors who are audit and supervisory committee members); to consider election of four directors who are audit and supervisory committee members; to consider determination of the remuneration amount for directors (excluding directors who are audit and supervisory committee members); to consider determination of the remuneration amount for directors who are audit and supervisory committee members; and to consider other matters.

Sumitomo Pharma Co., Ltd. expected to report Q1 2026 results on July 29, 2025. This event was calculated by S&P Global (Created on May 13, 2025).

Sumitomo Pharma Co., Ltd. proposed Amendment to the Articles of Incorporation at its AGM to be held on June 2025.

Sumitomo Pharma Co., Ltd. provided consolidated earnings guidance for the year ending March 31, 2026. For the year, the company expected revenue of JPY 355,000 million; Core operating profit of JPY 56,000 million; Operating profit of JPY 54,000 million; Net profit attributable to owners of parent of JPY 40,000 million; and Earnings per share of JPY 100.68.

Sumitomo Pharma Co., Ltd., Board Meeting, May 13, 2025. Agenda: To submit a proposal of a partial amendment to the Articles of Incorporation to the 205th Annual Shareholders' Meeting scheduled for June 2025.

Sumitomo Pharma Co., Ltd. revised consolidated earnings guidance for the year ending March 31, 2025. For the year, the company now expects net sales of JPY 398,800 million, Operating profit of JPY 28,800 million, Net profit attributable to owners of parent is expected to be JPY 23,600 million or JPY 59.49 earnings per share as compared to net sales of JPY 381,000 million, Operating profit of JPY 21,000, Net loss attributable to owners of parent is expected to be JPY 16,000 million and Basic earnings per share JPY 40.27 Revenue is now expected to be 398.8 billion JPY, up by 17.8 billion JPY from the previous forecast, as sales of ORGOVYX (therapeutic agent for advanced prostate cancer) and other products were higher than expected in the North America segment. Core operating profit has been revised up by 13.2 billion JPY from the previous forecast to 43.2 billion JPY. This is because selling, general and administrative expenses, as well as research and development expenses, are expected to be nearly in line with expectations, while gross profit is anticipated to increase due to higher revenue. Operating profit has been revised up by 7.8 billion JPY from the previous forecast to 28.8 billion JPY, due to the increase in core operating profit despite profit- reducing factors such as the recording of impairment losses on intangible assets. Net profit attributable to owners of the parent has been revised up by 7.6 billion JPY from the previous forecast to 23.6 billion JPY.

Sumitomo Pharma Co., Ltd. Presents at World Orphan Drug Congress USA 2025, Apr-23-2025 03:10 PM. Venue: Boston Convention & Exhibition Center, Boston, Massachusetts, United States. Speakers: Johanna Rossell, Senior Vice President, General Manager.

Marubeni Global Pharma Co., Ltd. entered into Share Transfer Agreement to acquire 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) for ¥45.0 billion on April 1, 2025. A cash consideration of ¥45 billion will be paid by Marubeni Global Pharma Co., Ltd. The transaction is subject to subject to antitrust regulations. The expected completion of the transaction is from July 1, 2025 to September 30, 2025.

Sumitomo Chemical Co., Ltd. announced that Sumitomo Pharma Co., Ltd. has resolved to establish a new wholly-owned subsidiary and transfer its business in Asia to the New Company through simplified absorption-type company split and then enter into a share transfer agreement to transfer 60% of the New Company's issued shares to Marubeni Global Pharma Inc. as well as a shareholders' agreement for the New Company. For details, please see the attachment. Ltd. ("SMPAP"), along with their subsidiaries, will be transferred to a wholly-owned subsidiary to be newly established by the Company ("the new company") through an absorption-type company split ("the absorption-type company split"), and that 60% of the newly issued shares of the new company will be transferred to Marubeni Global Pharma Corporation ("the share transfer" and "the share transfer agreement"); and a shareholders' agreement related to the new company ("the Shareholders' Agreement"). The split is a simplified absorption-type company split in which a wholly-owned subsidiary of the Company will be the succeeding company. A Summary of the Share Transfer Agreement and the Shareholders' Agreement. The share transfer agreement, which stipulates the following matters among others, shall be executed: the Company shall establish the new company and then execute an absorption-type company split agreement with the new company. The share transfer shall be executed on or after the effective date of this absorption-type company split. The Treatment of Share Options and Bonds with Share Options Following the Company Split Not applicable. The Increase or Decrease in Capital Due to the Company Split. There will be no increase or decrease in the Company's capital due to the company split. The Rights and Obligations to Be Succeeded by the Succeeding Company. The business is primarily operated by Sumitomo Pharma (China) and SMPAP and their subsidiaries.

Sumitomo Pharma Co., Ltd., 2025 Earnings Call, May 13, 2025

Sawai Group Holdings Co., Ltd. (TSE:4887) agreed to acquire FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on March 28, 2025. The expected completion of the transaction is June 30, 2025.

Sumitomo Pharma Co., Ltd., Board Meeting, Mar 28, 2025. Agenda: To consider and approve the 205th Annual Shareholders' Meeting to be held in June 2025.

Sumitomo Pharma Co., Ltd. announced that as of March 26, the Company has decided to refinance its existing borrowings (hereinafter referred to as "the Refinancing") through a syndicated loan (Tranche A: Term Loan, Tranche B: Commitment Line) (hereinafter referred to as "the Syndicated Loan Agreement"), as outlined below. The Company has repaid a portion of existing borrowings, including a bridge loan for the acquisition of Myovant Sciences Ltd. as a wholly owned subsidiary and existing borrowings for the strategic alliance with Roivant Sciences Ltd. implemented in December 2019, totaling JPY 331 billion, with the proceeds of JPY 98 billion from the sale of Roivant Sciences Ltd. shares, and has entered into new syndicated loan agreements as detailed below. Through the Refinancing, the Company aims to resolve the breach of financial covenants that occurred in the fiscal year ended March 2024 and to stabilize its financial position. Overview of the Syndicated Loan Agreement: Term Loan (Tranche A) is JPY 140 billion and Commitment Line (Tranche B) is JPY 93.0 billion. Loan/Commitment Period is March 31, 2025 to­ March 31, 2028. Repayment Method is Lump sum repayment on due date. Joint Guarantor is Sumitomo Chemical Co., Ltd. Arranger & Agent is Sumitomo Mitsui Banking Corporation. Co-Arranger is Sumitomo Mitsui Trust Bank, Limited. Participating Financial Institutions: Sumitomo Mitsui Banking Corporation; Sumitomo Mitsui Trust Bank, Limited; The Norinchukin Bank; Mizuho Bank, Ltd.; MUFG Bank, Ltd.; The Hyakujushi Bank, Ltd.; Aozora Bank, Ltd.; The Iyo Bank, Ltd.; San ju San Bank, Ltd.; The Shiga Bank, Ltd.; Joyo Bank, Ltd.; The Hiroshima Bank, Ltd.; The Oita Bank, Ltd.; The Chiba Bank, Ltd.; The Nanto Bank, Ltd.; and The Kiyo Bank, Ltd.

Terrapinn Holdings Ltd, World Orphan Drug Congress USA 2025, Apr 22, 2025 through Apr 24, 2025. Venue: Boston Convention & Exhibition Center, Boston, Massachusetts, United States.

Sumitomo Pharma Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025

From October 1, 2024 to December 31, 2024, the company has repurchased 20,269,486 shares, representing 2.76% for $237.53 million. With this, the company has completed the repurchase of 101,504,919 shares, representing 12.95% for $1,002.79 million under the buyback announced on April 2, 2024.

Sumitomo Pharma Co., Ltd. revised consolidated earnings guidance for the year ending March 31, 2025. For the year, the company expects net sales of JPY 381,000 million, Operating profit of JPY 21,000 million, Net profit attributable to owners of parent is expected to be JPY 16,000 million or JPY 40.27 earnings per share against net sales of JPY 338,000 million, Operating profit of JPY 0, Net loss attributable to owners of parent is expected to be JPY 16,000 million or JPY 40.27 Loss per share. Reasons for the revisions For the revised forecasts announced today, the Company has changed assumed exchange rates average exchange rates) for the full-year period from its previous forecasts of JPY 145.0 to JPY 152.0 against 1 USD and JPY 20.0 to JPY 21.0 against RMB 1. Revenue is now expected to be JPY 381.0 billion, up by JPY 43.0 billion from the previous forecast, as sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) and other products remain brisk in the North America segment while sales in China are exceeding plans in he Asia segment, on top of an increase due to the updated forex assumptions. Core operating profit has been revised up by JPY 29.0 billion from the previous forecast to JPY 30.0 billion. This is a result of an increase in gross profit associated with revenue increase, and an expectation that selling, general and administrative expenses and research and development expenses will remain flat due to a decrease in expenses owing to the business structure improvement at the Company, etc., despite an increase due to the updated forex assumptions. Operating profit has been revised to JPY 21.0 billion, up by JPY 21.0 billion from the previous forecast, because of the sheer magnitude of the increase in core operating profit despite the recording of expenses for business structure improvement and otherwise by the Company. Net profit attributable to owners of the parent has been revised to JPY 16.0 billion, reversing the previously forecasted loss of JPY 16.0 billion.

Sumitomo Pharma Co., Ltd. expected to report Fiscal Year 2025 results on May 13, 2025. This event was calculated by S&P Global (Created on January 31, 2025).

Sumitomo Pharma Co., Ltd. announced that Sumitomo Pharma has concluded a co-promotion collaboration partner agreement with Johnson & Johnson in Japan of the long-acting antipsychotic medication "XEPLION®? Aqueous Suspension for IM Injection 25 mg Syringe, "50 mg Syringe", "75 mg Syringe", "100 mg Syringe" and "150 mg Syringe," which are indicated for "schizophrenia," as well as "XEPLION TRI ®? Aqueous Suspended for IM Injection 175 mg Syringe, "263 mg Syringe" and "350 mg Syringe" and "525 mg Syringe, which are indicated for "sch schizophreniaia (only when appropriate treatment has been conducted with paliperidone every four weeks)" (generic name: paliperidone palmitate, collectively referred to as "the product"), currently marketed by Janssen Pharma in Japan. Purposes of this agreement. Sumitomo Pharma is working on various measures to achieve early business recovery and renewed growth, aiming to transform fiscal 2024 into a turning point for the growth of the Sumitomo Pharma group. Sumitomo Pharma focuses on the area of Psychiatry & Neurology as one of its priority disease areas for research and development, as well as focus areas in the Japanese market. Sumitomo Pharma has a strong marketing track record in the treatment of schizophrenia, including the sale of the atypical antipsychotic agent " Latuda ®?" and the antipsychotic agent "LONASEN ®? Tape," both created by Sumitomo Pharma. With the addition of XEPLION ®? and XEPLION TRI ®? to Sumitomo Pharma's lineup in the Psychiatry & Neurology area, Sumitomo Pharma aims to contribute to the treatment of more patients with schizophrenia. Details of this agreement. Sumitom Pharma will conduct promotional activities in collaboration with Janssen from around February 2025. In addition, Sumitomo Pharma also plans to assume responsibility for local distribution in the future. These products are long-lasting solutions administered at 4 or 12-week intervals for the treatment of schizophrenia.

Sumitomo Pharma Co., Ltd., Q3 2025 Earnings Call, Jan 31, 2025

From July 1, 2024 to October 1, 2024, the company has repurchased 9,984,350 shares, representing 1.35% for $116.88 million. With this, the company has completed the repurchase of 81,235,433 shares, representing 10.18% for $765.26 million under the buyback announced on April 2, 2024.

Sumitomo Pharma Co., Ltd. announced that they will report Q3, 2025 results at 3:30 PM, Tokyo Standard Time on Jan 31, 2025

Sumitomo Pharma Co., Ltd. expected to report Q3 2025 results on January 30, 2025. This event was calculated by S&P Global (Created on October 30, 2024).